Therefore, blocking the galectin-9/Tim-3 interaction in vivo may alleviate NPC exosome-mediated Th1 inhibition and maintenance of antitumor T cell responses. This evidence concerns the gene HAVCR2 and nasopharyngeal carcinoma.